|
1
|
Lynch HT, Lynch J, Conway T, Watson P,
Feunteun J, Lenoir G, Narod S and Fitzgibbons R Jr: Hereditary
breast cancer and family cancer syndromes. World J Surg. 18:21–31.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ford D, Easton DF, Bishop DT, Narod SA and
Goldgar DE: Risks of cancer in BRCA1-mutation carriers. Breast
Cancer Linkage Consortium. Lancet. 343:692–695. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sokolenko AP, Iyevleva AG, Mitiushkina NV,
Suspitsin EN, Preobrazhenskaya EV, Kuligina ESh, Voskresenskiy DA,
Lobeiko OS, Krylova NY, Gorodnova TV, Buslov KG, Bit-Sava EM,
Dolmatov GD, Porhanova NV, Polyakov IS, Abysheva SN, Katanugina AS,
Baholdin DV, Yanus GA, Togo AV, Moiseyenko VM, Maximov SY,
Semiglazov VF and Imyanitov EN: Hereditary breast-ovarian cancer
syndrome in Russia. Acta Nat. 2:31–35. 2010.PubMed/NCBI
|
|
4
|
Smith KL and Isaacs C: BRCA mutation
testing in determining breast cancer therapy. Cancer J. 17:492–499.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ruan Y, Song AP, Wang H, Xie YT, Han JY,
Sajdik C, Tian XX and Fang WG: Genetic polymorphisms in
AURKA and BRCA1 are associated with breast cancer
susceptibility in a Chinese Han population. J Pathol. 225:535–543.
2011.
|
|
6
|
Zhang B, Beeghly-Fadiel A, Long J and
Zheng W: Genetic variants associated with breast-cancer risk:
comprehensive research synopsis, meta-analysis, and epidemiological
evidence. Lancet Oncol. 12:477–488. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Narod SA and Salmena L: BRCA1 and BRCA2
mutations and breast cancer. Discov Med. 12:445–453.
2011.PubMed/NCBI
|
|
8
|
Vasickova P, Machackova E, Lukesova M,
Damborsky J, Horky O, Pavlu H, Kuklova J, Kosinova V, Navratilova M
and Foretova L: High occurrence of BRCA1 intragenic
rearrangements in hereditary breast and ovarian cancer syndrome in
the Czech Republic. BMC Med Genet. 8:322007.
|
|
9
|
Walsh T and King MC: Ten genes for
inherited breast cancer. Cancer Cell. 11:103–105. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Friedenson B: The BRCA1/2 pathway prevents
hematologic cancers in addition to breast and ovarian cancers. BMC
Cancer. 7:1522007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cortesi L, Masini C, Cirilli C, Medici V,
Marchi I, Cavazzini G, Pasini G, Turchetti D and Federico M:
Favourable ten-year overall survival in a Caucasian population with
high probability of hereditary breast cancer. BMC Cancer.
10:902010.PubMed/NCBI
|
|
12
|
Bolton KL, Chenevix-Trench G, Goh C,
Sadetzki S, Ramus SJ, Karlan BY, Lambrechts D, Despierre E,
Barrowdale D, McGuffog L, Healey S, Easton DF, Sinilnikova O,
Benítez J, García MJ, Neuhausen S, Gail MH, Hartge P, Peock S,
Frost D, Evans DG, Eeles R, Godwin AK, Daly MB, Kwong A, Ma ES,
Lázaro C, Blanco I, Montagna M, D'Andrea E, Nicoletto MO, Johnatty
SE, Kjær SK, Jensen A, Høgdall E, Goode EL, Fridley BL, Loud JT,
Greene MH, Mai PL, Chetrit A, Lubin F, Hirsh-Yechezkel G, Glendon
G, Andrulis IL, Toland AE, Senter L, Gore ME, Gourley C, Michie CO,
Song H, Tyrer J, Whittemore AS, McGuire V, Sieh W, Kristoffersson
U, Olsson H, Borg Å, Levine DA, Steele L, Beattie MS, Chan S,
Nussbaum RL, Moysich KB, Gross J, Cass I, Walsh C, Li AJ, Leuchter
R, Gordon O, Garcia-Closas M, Gayther SA, Chanock SJ, Antoniou AC
and Pharoah PD; EMBRACE; kConFab Investigators; Cancer Genome Atlas
Research Network. Association between BRCA1 and BRCA2
mutations and survival in women with invasive epithelial ovarian
cancer. JAMA. 307:382–390. 2012.
|
|
13
|
Dillenburg CV, Bandeira IC, Tubino TV,
Rossato LG, Dias ES, Bittelbrunn AC and Leistner-Segal S:
Prevalence of 185delAG and 5382insC mutations in BRCA1, and
6174delT in BRCA2 in women of Ashkenazi Jewish origin in
southern Brazil. Genet Mol Biol. 35:599–602. 2012.PubMed/NCBI
|
|
14
|
Ewald IP, Ribeiro PL, Palmero EI, Cossio
SL, Giugliani R and Ashton-Prolla P: Genomic rearrangements in
BRCA1 and BRCA2: a literature review. Genet Mol Biol.
32:437–446. 2009.
|
|
15
|
Dent R, Trudeau M, Pritchard KI, Hanna WM,
Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA:
Triple-negative breast cancer: clinical features and patterns of
recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gonzalez-Angulo AM, Timms KM, Liu S, Chen
H, Litton JK, Potter J, Lanchbury JS, Stemke-Hale K, Hennessy BT,
Arun BK, Hortobagyi GN, Do KA, Mills GB and Meric-Bernstam F:
Incidence and outcome of BRCA mutations in unselected
patients with triple receptor-negative breast cancer. Clin Cancer
Res. 17:1082–1089. 2011.
|
|
17
|
Young SR, Pilarski RT, Donenberg T,
Shapiro C, Hammond LS, Miller J, Brooks KA, Cohen S, Tenenholz B,
Desai D, Zandvakili I, Royer R, Li S and Narod SA: The prevalence
of BRCA1 mutations among young women with triple-negative breast
cancer. BMC Cancer. 9:862009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Holstege H, Joosse SA, van Oostrom CT,
Nederlof PM, de Vries A and Jonkers J: High incidence of
protein-truncating TP53 mutations in BRCA1-related breast
cancer. Cancer Res. 69:3625–3633. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yates MS, Meyer LA, Deavers MT, Daniels
MS, Keeler ER, Mok SC, Gershenson DM and Lu KH: Microscopic and
early-stage ovarian cancers in BRCA1/2 mutation carriers:
building a model for early BRCA-associated tumorigenesis. Cancer
Prev Res. 4:463–470. 2011.PubMed/NCBI
|
|
20
|
Tinker AV and Gelmon K: The role of PARP
inhibitors in the treatment of ovarian carcinomas. Curr Pharm Des.
18:3770–3774. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kaye SB, Lubinski J, Matulonis U, Ang JE,
Gourley C, Karlan BY, Amnon A, Bell-McGuinn KM, Chen LM,
Friedlander M, Safra T, Vergote I, Wickens M, Lowe ES, Carmichael J
and Kaufman B: Phase II, open-label, randomized, multicenter study
comparing the efficacy and safety of olaparib, a poly (ADP-ribose)
polymerase inhibitor, and pegylated liposomal doxorubicin in
patients with BRCA1 or BRCA2 mutations and recurrent ovarian
cancer. J Clin Oncol. 30:372–379. 2012. View Article : Google Scholar
|
|
22
|
Ledermann J, Harter P, Gourley C,
Friedlander M, Vergote I, Rustin G, Scott C, Meier W,
Shapira-Frommer R, Safra T, Matei D, Macpherson E, Watkins C,
Carmichael J and Matulonis U: Olaparib maintenance therapy in
platinum-sensitive relapsed ovarian cancer. N Engl J Med.
366:1382–1392. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Vaezi A, Feldman CH and Niedernhofer LJ:
ERCC1 and XRCC1 as biomarkers for lung and head and
neck cancer. Pharmgenomics Pers Med. 4:47–63. 2011.
|
|
24
|
Chen Y, Toland AE, McLennan J, Fridlyand
J, Crawford B, Costello JF and Ziegler JL: Lack of germ-line
promoter methylation in BRCA1-negative families with
familial breast cancer. Genet Test. 10:281–284. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Potapova A, Hoffman AM, Godwin AK,
Al-Saleem T and Cairns P: Promoter hypermethylation of the
PALB2 susceptibility gene in inherited and sporadic breast
and ovarian cancer. Cancer Res. 68:998–1002. 2008.
|
|
26
|
Lynch HT, Casey MJ, Snyder CL, Bewtra C,
Lynch JF, Butts M and Godwin AK: Hereditary ovarian carcinoma:
heterogeneity, molecular genetics, pathology, and management. Mol
Oncol. 3:97–137. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vogel VG, Costantino JP, Wickerham DL,
Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon
ER Jr, Wade JL III, Robidoux A, Margolese RG, James J, Lippman SM,
Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan
VC and Wolmark N; National Surgical Adjuvant Breast and Bowel
Project (NSABP). Effects of tamoxifen vs raloxifene on the risk of
developing invasive breast cancer and other disease outcomes: the
NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA.
295:2727–2741. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
McLaughlin JR, Risch HA, Lubinski J,
Moller P, Ghadirian P, Lynch H, Karlan B, Fishman D, Rosen B,
Neuhausen SL, Offit K, Kauff N, Domchek S, Tung N, Friedman E,
Foulkes W, Sun P and Narod SA: Hereditary Ovarian Cancer Clinical
Study Group: reproductive risk factors for ovarian cancer in
carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet
Oncol. 8:26–34. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Milne RL, Knight JA, John EM, Dite GS,
Balbuena R, Ziogas A, Andrulis IL, West DW, Li FP, Southey MC,
Giles GG, McCredie MR, Hopper JL and Whittemore AS: Oral
contraceptive use and risk of early-onset breast cancer in carriers
and noncarriers of BRCA1 and BRCA2 mutations. Cancer
Epidemiol Biomarkers Prev. 14:350–356. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Domanska K, Malander S, Staaf J, Karlsson
A, Borg A, Jönsson G and Nilbert M: Genetic profiles distinguish
different types of hereditary ovarian cancer. Oncol Rep.
24:885–895. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lotsari JE, Gylling A, Abdel-Rahman WM,
Nieminen TT, Aittomäki K, Friman M, Pitkänen R, Aarnio M, Järvinen
HJ, Mecklin JP, Kuopio T and Peltomäki P: Breast carcinoma and
Lynch syndrome: molecular analysis of tumors arising in mutation
carriers, non-carriers, and sporadic cases. Breast Cancer Res.
14:R902012. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Meyer LA, Broaddus RR and Lu KH:
Endometrial cancer and Lynch syndrome: clinical and pathologic
considerations. Cancer Control. 16:14–22. 2009.PubMed/NCBI
|
|
33
|
Masuda K, Banno K, Yanokura M, Kobayashi
Y, Kisu I, Ueki A, Ono A, Nomura H, Hirasawa A, Susumu N and Aoki
D: Carcinoma of the lower uterine segment (LUS):
clinicopathological characteristics and association with lynch
syndrome. Curr Genomics. 12:25–29. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Crijnen TE, Janssen-Heijnen ML, Gelderblom
H, Morreau J, Nooij MA, Kenter GG and Vasen HF: Survival of
patients with ovarian cancer due to a mismatch repair defect. Fam
Cancer. 4:301–305. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kim MK, Song SY, Do IG, Kim SH, Choi CH,
Kim TJ, Lee JW, Bae DS and Kim BG: Synchronous gynecologic
malignancy and preliminary results of Lynch syndrome. J Gynecol
Oncol. 22:233–238. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Williams SA, Wilson JB, Clark AP,
Mitson-Salazar A, Tomashevski A, Ananth S, Glazer PM, Semmes OJ,
Bale AE, Jones NJ and Kupfer GM: Functional and physical
interaction between the mismatch repair and FA-BRCA pathways. Hum
Mol Genet. 20:4395–4410. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Vogel VG, Costantino JP, Wickerham DL,
Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon
ER, Wade JL III, Robidoux A, Margolese RG, James J, Runowicz CD,
Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC and
Wolmark N: National Surgical Adjuvant Breast and Bowel Project:
Update of the National Surgical Adjuvant Breast and Bowel Project
Study of tamoxifen and raloxifene (STAR) P-2 trial: preventing
breast cancer. Cancer Prev Res. 3:696–706. 2010. View Article : Google Scholar
|
|
38
|
Burga LN, Hu H, Juvekar A, Tung NM, Troyan
SL, Hofstatter EW and Wulf GM: Loss of BRCA1 leads to an
increase in epidermal growth factor receptor expression in mammary
epithelial cells, and epidermal growth factor receptor inhibition
prevents estrogen receptor-negative cancers in BRCA1-mutant
mice. Breast Cancer Res. 13:R302011.PubMed/NCBI
|
|
39
|
Uray IP and Brown PH: Chemoprevention of
hormone receptor-negative breast cancer: new approaches needed.
Recent Results Cancer Res. 188:147–162. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Saito M, Matsuzaki M, Sakuma T, Katagata
N, Watanabe F, Yamaguchi Y, Schetter AJ, Takenoshita S and Nomizu
T: Clinicopathological study of non-palpable familial breast cancer
detected by screening mammography and diagnosed as DCIS. Breast
Cancer. Aug 9–2012.(Epub ahead of print).
|
|
41
|
Yabuuchi H, Matsuo Y, Sunami S, Kamitani
T, Kawanami S, Setoguchi T, Sakai S, Hatakenaka M, Kubo M, Tokunaga
E, Yamamoto H and Honda H: Detection of non-palpable breast cancer
in asymptomatic women by using unenhanced diffusion-weighted and
T2-weighted MR imaging: comparison with mammography and dynamic
contrast-enhanced MR imaging. Eur Radiol. 21:11–17. 2011.
View Article : Google Scholar
|
|
42
|
Passaperuma K, Warner E, Causer PA, Hill
KA, Messner S, Wong JW, Jong RA, Wright FC, Yaffe MJ, Ramsay EA,
Balasingham S, Verity L, Eisen A, Curpen B, Shumak R, Plewes DB and
Narod SA: Long-term results of screening with magnetic resonance
imaging in women with BRCA mutations. Br J Cancer. 107:24–30. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Warner E, Hill K, Causer P, Plewes D, Jong
R, Yaffe M, Foulkes WD, Ghadirian P, Lynch H, Couch F, Wong J,
Wright F, Sun P and Narod SA: Prospective study of breast cancer
incidence in women with a BRCA1 or BRCA2 mutation
under surveillance with and without magnetic resonance imaging. J
Clin Oncol. 29:1664–1669. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Westin SN, Sun CC, Lu KH, Schmeler KM,
Soliman PT, Lacour RA, Johnson KG, Daniels MS, Arun BK, Peterson SK
and Bodurka DC: Satisfaction with ovarian carcinoma risk-reduction
strategies among women at high risk for breast and ovarian
carcinoma. Cancer. 117:2659–2667. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Dohrn L, Salles D, Siehler SY, Kaufmann J
and Wiesmüller L: BRCA1-mediated repression of mutagenic
end-joining of DNA double-strand breaks requires complex formation
with BACH1. Biochem J. 441:919–926. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Corso G, Marrelli D, Pascale V, Vindigni C
and Roviello F: Frequency of CDH1 germline mutations in gastric
carcinoma coming from high- and low-risk areas: metanalysis and
systematic review of the literature. BMC Cancer. 12:82012.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Chun N and Ford JM: Genetic testing by
cancer site: stomach. Cancer J. 18:355–363. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Lytras A and Tolis G: Reproductive
disturbances in multiple neuroendocrine tumor syndromes. Endocr
Relat Cancer. 16:1125–1138. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Melbārde-Gorkuša I, Irmejs A, Bērzin̦a D,
Strumfa I, Abolin̦š A, Gardovskis A, Subatniece S, Trofimovičs G,
Gardovskis J and Miklaševičs E: Challenges in the management of a
patient with Cowden syndrome: case report and literature review.
Hered Cancer Clin Pract. 10:52012.PubMed/NCBI
|
|
50
|
Buller RE, Lallas TA, Shahin MS, Sood AK,
Hatterman-Zogg M, Anderson B, Sorosky JI and Kirby PA: The
p53 mutational spectrum associated with BRCA1 mutant
ovarian cancer. Clin Cancer Res. 7:831–838. 2001.
|
|
51
|
Meng AG and Jiang LL: Induction of G2/M
arrest by pseudolaric acid B is mediated by activation of the ATM
signaling pathway. Acta Pharmacol Sin. 30:442–450. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Lindeman GJ, Hiew M, Visvader JE, Leary J,
Field M, Gaff CL, Gardner RJ, Trainor K, Cheetham G, Suthers G and
Kirk J: Frequency of the ATM IVS10-6T>G variant in Australian
multiple-case breast cancer families. Breast Cancer Res.
6:R401–R407. 2004. View
Article : Google Scholar
|
|
53
|
Wang X, Kennedy RD, Ray K, Stuckert P,
Ellenberger T and D'Andrea AD: Chk1-mediated phosphorylation of
FANCE is required for the Fanconi anemia/BRCA pathway. Mol Cell
Biol. 27:3098–3108. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Kuusisto KM, Bebel A, Vihinen M,
Schleutker J and Sallinen SL: Screening for BRCA1,
BRCA2, CHEK2, PALB2, BRIP1,
RAD50, and CDH1 mutations in high-risk Finnish
BRCA1/2-founder mutation-negative breast and/or ovarian
cancer individuals. Breast Cancer Res. 13:R202011.PubMed/NCBI
|
|
55
|
de Garibay GR, Díaz A, Gaviña B, Romero A,
Garre P, Vega A, Blanco A, Tosar A, Díez O, Pérez-Segura P,
Díaz-Rubio E, Caldés T and de la Hoya M: Low prevalence of SLX4
loss-of-function mutations in non-BRCA1/2 breast and/or ovarian
cancer families. Eur J Hum Genet. Dec 5–2012.(Epub ahead of
print).
|
|
56
|
Seal S, Thompson D, Renwick A, Elliott A,
Kelly P, Barfoot R, Chagtai T, Jayatilake H, Ahmed M, Spanova K,
North B, McGuffog L, Evans DG, Eccles D, Easton DF, Stratton MR and
Rahman N; Breast Cancer Susceptibility Collaboration (UK).
Truncating mutations in the Fanconi anemia J gene BRIP1 are
low-penetrance breast cancer susceptibility alleles. Nat Genet.
38:1239–1241. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
57
|
Sy SM, Huen MS and Chen J: PALB2 is an
integral component of the BRCA complex required for homologous
recombination repair. Proc Natl Acad Sci USA. 106:7155–7160. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Willers H, Kachnic LA, Luo CM, Li L,
Purschke M, Borgmann K, Held KD and Powell SN: Biomarkers and
mechanisms of FANCD2 function. J Biomed Biotechnol.
2008:8215292008. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Johnson N, Li YC, Walton ZE, Cheng KA, Li
D, Rodig SJ, Moreau LA, Unitt C, Bronson RT, Thomas HD, Newell DR,
D'Andrea AD, Curtin NJ, Wong KK and Shapiro GI: Compromised CDK1
activity sensitizes BRCA-proficient cancers to PARP inhibition. Nat
Med. 17:875–882. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Clague J, Wilhoite G, Adamson A, Bailis A,
Weitzel JN and Neuhausen SL: RAD51C germline mutations in
breast and ovarian cancer cases from high-risk families. PLoS One.
6:e256322011. View Article : Google Scholar
|
|
61
|
Hsu HM, Wang HC, Chen ST, Hsu GC, Shen CY
and Yu JC: Breast cancer risk is associated with the genes encoding
the DNA double-strand break repair Mre11/Rad50/Nbs1 complex. Cancer
Epidemiol Biomarkers Prev. 16:2024–2032. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Meindl A, Hellebrand H, Wiek C, Erven V,
Wappenschmidt B, Niederacher D, Freund M, Lichtner P, Hartmann L,
Schaal H, Ramser J, Honisch E, Kubisch C, Wichmann HE, Kast K,
Deissler H, Engel C, Muller-Myhsok B, Neveling K, Kiechle M, Mathew
CG, Schindler D, Schmutzler RK and Hanenberg H: Germline mutations
in breast and ovarian cancer pedigrees establish RAD51C as a human
cancer susceptibility gene. Nat Genet. 42:410–414. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Pelttari LM, Heikkinen T, Thompson D,
Kallioniemi A, Schleutker J, Holli K, Blomqvist C, Aittomäki K,
Bützow R and Nevanlinna H: RAD51C is a susceptibility gene
for ovarian cancer. Hum Mol Genet. 20:3278–3288. 2011. View Article : Google Scholar
|
|
64
|
Esteban Cardeñosa E, de Juan Jiménez I,
Palanca Suela S, Chirivella González I, Segura Huerta A, Santaballa
Beltran A, Casals El Busto M, Barragán González E, Fuster Lluch O,
Bermúdez Edo J and Bolufer Gilabert P: Low penetrance alleles as
risk modifiers in familial and sporadic breast cancer. Fam Cancer.
11:629–636. 2012.PubMed/NCBI
|
|
65
|
Jakubowska A, Gronwald J, Menkiszak J,
Górski B, Huzarski T, Byrski T, Edler L, Lubiński J, Scott RJ and
Hamann U: The VEGF_936_C>T 3′UTR polymorphism reduces
BRCA1-associated breast cancer risk in Polish women. Cancer
Lett. 262:71–76. 2008.
|
|
66
|
Runnebaum IB, Wang-Gohrke S, Vesprini D,
Kreienberg R, Lynch H, Moslehi R, Ghadirian P, Weber B, Godwin AK,
Risch H, Garber J, Lerman C, Olopade OI, Foulkes WD, Karlan B,
Warner E, Rosen B, Rebbeck T, Tonin P, Dubé MP, Kieback DG and
Narod SA: Progesterone receptor variant increases ovarian cancer
risk in BRCA1 and BRCA2 mutation carriers who were never exposed to
oral contraceptives. Pharmacogenetics. 11:635–638. 2001. View Article : Google Scholar
|
|
67
|
Ratner E, Lu L, Boeke M, Barnett R, Nallur
S, Chin LJ, Pelletier C, Blitzblau R, Tassi R, Paranjape T, Hui P,
Godwin AK, Yu H, Risch H, Rutherford T, Schwartz P, Santin A,
Matloff E, Zelterman D, Slack FJ and Weidhaas JB: A
KRAS-variant in ovarian cancer acts as a genetic marker of
cancer risk. Cancer Res. 70:6509–6515. 2010.
|
|
68
|
Ripperger T, Gadzicki D, Meindl A and
Schlegelberger B: Breast cancer susceptibility: current knowledge
and implications for genetic counselling. Eur J Hum Genet.
17:722–731. 2009. View Article : Google Scholar : PubMed/NCBI
|
